Clinical Trial Update: Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial is studying a neoadjuvant combination of dupilumab, pembrolizumab, paclitaxel, and carboplatin in locally advanced triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Dupilumab (dupilumab)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Rima Patel | Conditions: Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | EARLY_Phase 1 | Status: RECRUITING